Volequin
Categoria
Volequin Nombres de marca, Volequin Analogos
Volequin Marca los nombres de mezcla
Volequin Formula quimica
C36H42F2N6O9
Volequin RX enlace
http://www.rxlist.com/cgi/generic2/quixin.htm
Volequin FDA hoja
Volequin MSDS (hoja de seguridad de materiales)
Volequin Sintesis de referencia
Mitscher, Lester A. et al;. J.Med.Chem;. 30, 12, 2283 hasta 2286 (1987)
Volequin Peso molecular
740.751 g/mol
Volequin Punto de fusion
No information avaliable
Volequin H2O Solubilidad
Insoluble
Volequin Estado
Solid
Volequin LogP
1.268
Volequin Formas de dosificacion
Tableta, líquido, la solución
Volequin Indicacion
Para el tratamiento de la conjuntivitis bacteriana causada por cepas susceptibles de los siguientes organismos: Corynebacterium spp, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, , Streptococcus (grupos C / F / G), estreptococos del grupo viridans, Acinetobacter lwoffii, Haemophilus influenzae, Serratia marcescens.
Volequin Farmacologia
Levofloxacina, una fluoroquinolona antiinfeccioso, es ópticamente activos L-isómero de ofloxacino. Levofloxacino se usa para tratar la conjuntivitis bacteriana, sinusitis, bronquitis crónica, neumonía adquirida en la comunidad y neumonía causada por cepas resistentes a penicilina de Streptococcus pneumoniae, infecciones de la piel y estructura de la piel, infecciones complicadas del tracto urinario y pielonefritis aguda.
Volequin Absorcion
La absorción de ofloxacino tras dosis únicas o múltiples de 200 a 400 mg es predecible, y la cantidad de fármaco absorbido aumenta proporcionalmente con la dosis.
Volequin Toxicidad
Los efectos secundarios incluyen desorientación, mareos, somnolencia, sofocos y frío, náuseas, dificultad en el habla, la hinchazón y entumecimiento en la cara
Volequin Informacion de Pacientes
PATIENT INFORMATION
While taking ofloxacin patient should be advised to:
� to drink fluids liberally;
� that mineral supplements, vitamins with iron or minerals, calcium- , aluminum-, or magnesium-based antacids, sucralfate or Videx�, (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution should not be taken within the two-hour period before or within the two-hour period after taking ofloxacin;
� that ofloxacin can be taken without regard to meals;
� that ofloxacin may cause neurologic adverse effects (e. g. , dizziness, lightheadedness) and that patients should know how they react to ofloxacin before they operate an automobile or machinery or engage in activities requiring mental alertness and coordination;
� to discontinue treatment and inform their physician if they experience pain, inflammation, or rupture of a tendon, and to rest and refrain from exercise until the diagnosis of tendinitis or tendon rupture has been confidently excluded;
� that ofloxacin may be associated with hypersensitivity reactions, even following the first dose, to discontinue the drug at the first sign of a skin rash, hives or other skin reactions, a rapid heartbeat, difficulty in swallowing or breathing, any swelling suggesting angioedema (e. g. , swelling of the lips, tongue, face; tightness of the throat, hoarseness), or any other symptom of an allergic reaction
� to avoid excessive sunlight or artificial ultraviolet light while receiving ofloxacin and to discontinue therapy if phototoxicity (e. g. , skin eruption) occurs;
� that if they are diabetic and are being treated with insulin or an oral hypoglycemic drug, to discontinue ofloxacin immediately if a hypoglycemic reaction occurs and consult a physician;
� that convulsions have been reported in patients taking quinolones, including ofloxacin, and to notify their physician before taking this drug if there is a history of this condition.
While taking ofloxacin patient should be advised to:
� to drink fluids liberally;
� that mineral supplements, vitamins with iron or minerals, calcium- , aluminum-, or magnesium-based antacids, sucralfate or Videx�, (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution should not be taken within the two-hour period before or within the two-hour period after taking ofloxacin;
� that ofloxacin can be taken without regard to meals;
� that ofloxacin may cause neurologic adverse effects (e. g. , dizziness, lightheadedness) and that patients should know how they react to ofloxacin before they operate an automobile or machinery or engage in activities requiring mental alertness and coordination;
� to discontinue treatment and inform their physician if they experience pain, inflammation, or rupture of a tendon, and to rest and refrain from exercise until the diagnosis of tendinitis or tendon rupture has been confidently excluded;
� that ofloxacin may be associated with hypersensitivity reactions, even following the first dose, to discontinue the drug at the first sign of a skin rash, hives or other skin reactions, a rapid heartbeat, difficulty in swallowing or breathing, any swelling suggesting angioedema (e. g. , swelling of the lips, tongue, face; tightness of the throat, hoarseness), or any other symptom of an allergic reaction
� to avoid excessive sunlight or artificial ultraviolet light while receiving ofloxacin and to discontinue therapy if phototoxicity (e. g. , skin eruption) occurs;
� that if they are diabetic and are being treated with insulin or an oral hypoglycemic drug, to discontinue ofloxacin immediately if a hypoglycemic reaction occurs and consult a physician;
� that convulsions have been reported in patients taking quinolones, including ofloxacin, and to notify their physician before taking this drug if there is a history of this condition.
Volequin Organismos afectados
Bacterias entéricas y otras eubacterias
